Efficacy and Safety of Canagliflozin As Add-On Therapy to Metformin in Type 2 Diabetes

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2015 Jul 2

PMID 26130867

Citations 3

Authors

Dawn M Battise

Affiliations

Soon will be listed here.

Citing Articles

Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study.

Aneja P, Bhalla G, Parvesh N, Aneja K, Aneja K Indian J Endocrinol Metab. 2019; 23(3):307-311.

PMID: 31641632 PMC: 6683679. DOI: 10.4103/ijem.IJEM_55_19.

Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes.

Bolge S, Flores N, Huang S, Cai J Int J Gen Med. 2017; 10:177-187.

PMID: 28694704 PMC: 5491699. DOI: 10.2147/IJGM.S138583.

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.

Wysham C, Lefebvre P, Pilon D, Ingham M, Lafeuille M, Emond B BMC Endocr Disord. 2017; 17(1):32.

PMID: 28595617 PMC: 5465542. DOI: 10.1186/s12902-017-0180-8.

References

Neal B, Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Stein P . Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013; 166(2):217-223.e11. DOI: 10.1016/j.ahj.2013.05.007. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

Abdul-Ghani M, Norton L, DeFronzo R . Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011; 32(4):515-31. DOI: 10.1210/er.2010-0029. View

Yale J, Bakris G, Cariou B, Yue D, David-Neto E, Xi L . Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013; 15(5):463-73. PMC: 3654568. DOI: 10.1111/dom.12090. View

Jendle J, Nauck M, Matthews D, Frid A, Hermansen K, During M . Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009; 11(12):1163-72. DOI: 10.1111/j.1463-1326.2009.01158.x. View

Schernthaner G, Gross J, Rosenstock J, Guarisco M, Fu M, Yee J . Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36(9):2508-15. PMC: 3747923. DOI: 10.2337/dc12-2491. View

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde A . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97(3):1020-31. DOI: 10.1210/jc.2011-2260. View

Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomgarden Z, Bush M . American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract. 2013; 19(3):536-57. PMC: 4142590. DOI: 10.4158/EP13176.CS. View

Bagust A, Beale S . Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003; 96(4):281-8. DOI: 10.1093/qjmed/hcg040. View

10.

Neumiller J, White Jr J, Campbell R . Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010; 70(4):377-85. DOI: 10.2165/11318680-000000000-00000. View

11.

DeFronzo R, Banerji M, Bray G, Buchanan T, Clement S, Henry R . Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009; 9:17. PMC: 2725044. DOI: 10.1186/1472-6823-9-17. View

12.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View